Clinical Trial Update: Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating gemcitabine and split-dose cisplatin plus everolimus (RAD001) in patients with advanced solid tumors, including bladder cancer and ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Renal Pelvis Cancer
• Ureteral Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Everolimus (everolimus)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Bladder Cancer, Renal Pelvis Cancer | Phase 1 | Status: COMPLETED